Company Encyclopedia
View More
name
Claymore/Zacks Yld Hog
CVY.US
News
View More

Peabody Energy Corporation (NYSE:BTU) Receives Average Rating of "Hold" from Brokerages

Peabody Energy Corporation (NYSE:BTU) has received an average "Hold" rating from seven analysts. The stock has mixed recommendations: two "sell," one "hold," and four "buy." The average 12-month price target is $27.00. Recent analyst actions include Benchmark raising its price target to $32.00 and Zacks Research downgrading to "strong sell." Peabody's stock opened at $29.54, with a market cap of $3.59 billion. The company reported a quarterly revenue of $1.01 billion, down 7% year-over-year.

Market Beat·
US
BTU
+0.27%
Market Beat·
US
BTU
+0.27%

Investors Purchase High Volume of APA Call Options (NASDAQ:APA)

APA Corporation (NASDAQ:APA) experienced a significant increase in call options trading, with 21,526 options acquired, marking an 85% rise from the average daily volume. Analysts have mixed ratings on APA, with a consensus 'Hold' rating and a target price of $25.90. Institutional investors have adjusted their stakes, and APA's stock performance shows a recent increase, trading at $26.56. The company reported strong quarterly earnings, beating estimates, and announced a quarterly dividend of $0.25 per share.

Market Beat·
US
APA
-0.89%
Market Beat·
US
APA
-0.89%

European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading

European equities traded in the US as American depositary receipts were flat on Thursday, rising 0.07% on the S&P Europe Select ADR Index. Gainers included SAP, DBV Technologies, Banco Bilbao Vizcaya Argentaria, and Ascendis Pharma. Decliners included Royal Philips, EDAP TMS, Materialise, and Criteo. From the UK and Ireland, gainers were Autolus Therapeutics, WPP, Bicycle Therapeutics, and Pearson. Decliners were Biodexa Pharmaceuticals, Trinity Biotech, Prudential, and Carnival.

fidelity·
US
BBVA
+1.14%
fidelity·
US
BBVA
+1.14%

Is Halliburton Stock Outperforming the S&P 500?

Is Halliburton Stock Outperforming the S&P 500?

Barchart Option·
US
HAL
+1.57%
Barchart Option·
US
HAL
+1.57%

Denali Therapeutics Secures $275 Million Royalty Deal With Royalty Pharma

Denali Therapeutics Inc. has partnered with Royalty Pharma plc in a $275 million synthetic royalty funding agreement for tividenofusp alfa, an investigational therapy for Hunter syndrome. Royalty Pharma will pay $200 million upon FDA approval and $75 million upon European approval by 2029. In return, they will receive a 9.25% royalty on worldwide net sales until a specified return multiple is reached.

Reuters·
US
RPRX
-1.14%
US
DNLI
+5.84%
Reuters·
US
RPRX
-1.14%
US
DNLI
+5.84%
© 2025 Longbridge｜Disclaimer